- Home
- ADM vs BIIB Comparison
ADM vs BIIB Comparison
Compare ADM & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADM
- BIIB
- Stock Information
- Founded
- ADM 1902
- BIIB 1978
- Country
- ADM United States
- BIIB United States
- Employees
- ADM N/A
- BIIB N/A
- Industry
- ADM Packaged Foods
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- ADM Consumer Staples
- BIIB Health Care
- Exchange
- ADM Nasdaq
- BIIB Nasdaq
- Market Cap
- ADM 23.1B
- BIIB 18.8B
- IPO Year
- ADM N/A
- BIIB 1991
- Fundamental
- Price
- ADM $53.61
- BIIB $127.04
- Analyst Decision
- ADM Hold
- BIIB Buy
- Analyst Count
- ADM 6
- BIIB 27
- Target Price
- ADM $49.67
- BIIB $187.83
- AVG Volume (30 Days)
- ADM 3.5M
- BIIB 1.5M
- Earning Date
- ADM 07-29-2025
- BIIB 07-31-2025
- Dividend Yield
- ADM 3.82%
- BIIB N/A
- EPS Growth
- ADM N/A
- BIIB 26.39
- EPS
- ADM 2.81
- BIIB 10.12
- Revenue
- ADM $83,858,000,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- ADM N/A
- BIIB N/A
- Revenue Next Year
- ADM $2.73
- BIIB N/A
- P/E Ratio
- ADM $19.01
- BIIB $12.56
- Revenue Growth
- ADM N/A
- BIIB 1.59
- 52 Week Low
- ADM $40.98
- BIIB $110.04
- 52 Week High
- ADM $66.08
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- ADM 72.20
- BIIB 46.07
- Support Level
- ADM $48.20
- BIIB $125.24
- Resistance Level
- ADM $55.05
- BIIB $136.84
- Average True Range (ATR)
- ADM 1.15
- BIIB 3.04
- MACD
- ADM 0.66
- BIIB -0.89
- Stochastic Oscillator
- ADM 82.52
- BIIB 15.52
About ADM Archer-Daniels-Midland Company
Archer-Daniels-Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. The company is also one of the largest grain merchandisers through its extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients and is a large producer of corn-based sweeteners, starches, and ethanol.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.